Comparative behavioural profile of newer antianxiety drugs on different mazes

Indian Journal of Experimental Biology

Volumn 46, Issue 9, 2008, Pages 633-639

  Kulkarni, Shrinivas K ^a,b   Singh, Kulwinder ^a   Bishnoi, Mahendra ^b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Antiepileptic; Anxiety; Atypical antipsychotic; Mazes

Indexed keywords

WITHANIA SOMNIFERA;

ANXIOLYTIC AGENT;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; MALE; MAZE TEST; MOUSE;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; MALE; MAZE LEARNING; MICE;

EID: 67549149201     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kulkarni S K & Reddy D S, Animal behavioural models for testing anti-anxiety agents, Methods and Finding in Expt and Clin Pharmacol, 18(3) (1996) 219.
2. Roy-Byrne P P, The GABA-benzodiazepines receptor complex: structure function and role in anxiety, J Clin Psychiatry, 66 (2005) 14.
3. Schwartz T L & Nihalni N, History repeats itself: pharmacodynamics trends in treatment of anxiety disorders, Current Pharmaceutical Design, 11 (2005) 255.
4. Zohar J & Westenberg H G, Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors, Acta Psychiatr Scand, 403 (2000) 39.
5. Fish E W, Faccidomo S, Gupta S & Miczek K A, Anxiolyticlike effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups, J Pharmacol Exp Ther, 308(2) (2004) 474.
6. Megna J L, Iqbal M M & Aneja A, Pharmacology and Therapeutics of gabapentin in the treatment of psychiatric disorders; present and future perspectives, Current Neuropharmacology, 1 (2003) 187.
7. Petty F, Brannan S, Casada J, Davis L L, Gajewski V, Kramer G L, Stone R C, Teten A L, Worchel J & Young K A, Olanzapine treatment for post-traumatic stress disorder: an open-label study, Int Clin Psychopharmacol, 16(6) 2001 331.
8. Meoni P & Hackett D, Characterization of the longitudinal course of long-term venlafaxine XR treatment of GAD, Int J Neuropsychopharmacol, 3 (2000) S282.
9. Bhattacharya S K, Bhattacharya A, Sairam K & Ghosal S, Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study, Phytomedicine, 7(6) (2000) 463.
10. Kulkarni S K, Singh K & Bishnoi M, Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs, Methods Find Exp Clin Pharmacol, 29(5) (2007) 343.
11. Shepherd J K & Grewal S S, Behavioral and pharmacological characterization of the elevated "zero maze" as an animal model of anxiety, Psychopharmacology 116 (1994) 56.
12. Kulkarni S K, Singh K & Bishnoi M, Involvement of adenosinergic receptors in anxiety related behaviours, Indian J Exp Biol, 45(5) (2007) 439.
13. rd edition), Vallabh Prakashan, New Delhi 1999.
14. Berger W, Portella C M, Fontenelle L F, Kinrys G & Mendlowicz M V, Antipsychotics, anticonvulsants, antiadrenergics and other drugs: what to do when posttraumatic stress disorder does not respond to selective serotonin reuptake inhibitors? Rev Bras Psiquiatr, 29 (2007) S61-5.
15. Schwartz T L & Nihalani N, Tiagabine in anxiety disorders, Expert Opin Pharmacother, 7(14) (2006) 1977.
16. Pollack M H, Matthews J & Scott E L, Gabapentin as a potential treatment for anxiety disorders, Am J Psychiatry 155 (1998) 992.
17. Taylor C P, Gee N S, Su T Z, Kocsis J D, Welty D F & Brown J P, A summary of mechanistic hypotheses of gabapentin pharmacology, Epilepsy Research, 29(3) (1998) 233.
18. Ghaemi S N, Katzow J J, Desai S P & Goodwin F, Gabapentin treatment of mood disorders: a preliminary study, J Clin Psychiatry, 59 (1998) 426.
19. Pande A C, Polack M H, Crockatt J, Greiner M, Chouinard G, Lydiard R B, Taylor C B, Dager S R & Shiovitz T, Placebo-Controlled Study of gabapentin treatment of panic disorder, J Clin Psychopharmacol, 20 (2000) 467.
20. Canuso C, Gharabawi G, Bouhours P, Leblanc J, Dunbar F & Rapaport M H, Results from open -label phase of arise-rd (augmentation with risperidone in resistant depression), Int J Psychopharmacology, 7 (2004) S345.
21. Davidson J R, DuPont R L, Hedges D & Haskins J T, Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder, J Clin Psychiat, 60(8) (1999) 528.